Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NSC-CRAd-S-pk7 in newly diagnosed malignant glioma
NCT03072134Phase 1Completed
- Sponsor
- Northwestern University
- Start
- Apr 2017
- Primary completion
- Apr 2020
- Modality
- Oncolytic Viruses, Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of NSC-CRAd-Survivin-pk7 in malignant glioma (2 arms), sponsored by Northwestern University. Primary endpoint: Percentage of Dose-limiting Toxicities at 2 years. Started Apr 2017; status: completed.
02
Drugs
NSC-CRAd-Survivin-pk7
03
Conditions
malignant glioma
Beyond the preview
Go deeper on NCT03072134.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03072134.